HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Patients with liver metastasis from esophagus squamous (ESC) are usually offered systemic
therapy. However, for those with predominant liver disease or failure of system therapy,
local liver management becomes an option. This prospective single center study aimed to
evaluate the efficacy and adverse events of hepatic arterial infusion chemotherapy (HAIC)
using percutaneous catheter placement techniques for liver metastases from esophagus squamous
(ESC).